CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?
CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus.
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?
CRMD stock sinks 27% in 3 months as its bearish 2026 outlook for DefenCath clouds near-term growth, raising investor concern.
CorMedix Inc. (CRMD) Analyst/Investor Day Transcript
CorMedix Inc. (CRMD) Analyst/Investor Day Transcript
CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside
CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?
CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?
CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?
CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?
CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.
CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Are Investors Undervaluing CorMedix (CRMD) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.
